One of the greatest enigmas in thrombosis research is the observation that one can diagnose a person with a thrombotic risk with a prolongation of the clotting time. Our textbooks have taught us that prolongation of clotting correlates with a tendency to bleed. To confuse our textbook knowledge further, the same patients often have a prolonged bleeding time, a diagnostic test to detect a dysfunction in primary haemostasis. In this paper we critically review the literature that tries to explain the contradiction that exists between in-vitro diagnostic tests and the observed clinical manifestations and discuss our current opinion on how antiphospholipid antibodies can disturb the haemostatic balance.
Miyakis S., Lockshin MD, Atsumi T., et al. International consensus statement on an update of the classification criteria for definite antiphospholipid syndrome (APS). J Thromb Haemost2006; 4: 295-306.
2.
Arnout J., Vermylen J.Current status and implications of autoimmune antiphospholipid antibodies in relation to thrombotic disease. J Thromb Haemost2003; 1: 931-942.
3.
Urbanus RT, Derksen RH, de Groot PGCurrent insight into diagnostics and pathophysiology of the antiphospholipid syndrome. Blood Rev2008; 22: 93-105.
4.
Galli M., Luciani D., Bertolini G., Barbui T.Lupus anticoagulants are stronger risk factors for thrombosis than anticardiolipin antibodies in the antiphospholipid syndrome: a systematic review of the literature . Blood2003; 101: 1827-1832.
5.
Simmelink MJA , Derksen Rhwm, Arnout J., de Groot PGA simple method to discriminate between β2-glycoprotein- and prothrombin-dependent lupus anticoagulants. J Thromb Haemost2003; 1: 740-747.
6.
de Laat HB, Derksen Rhwm, Urbanus RT, Roest M., de Groot PGβ2-Glycoprotein I dependent lupus anticoagulant highly correlates with thrombosis in the antiphospholipid syndrome. Blood2004; 104: 3598-3602.
7.
Iverson GM, Reddel S., Victoria EJ, et al. Use of single point mutations in domain I of beta 2-glycoprotein I to determine fine antigenic specificity of antiphospholipid autoantibodies . J Immunol2002; 169: 7097-7103.
8.
De Laat B., Derksen RH, Urbanus RT, de Groot PGIgG antibodies that recognize epitope Gly40-Arg43 in domain I of β2-glycoprotein I cause LAC and their presence correlates strongly with thrombosis. Blood2005; 105: 1540-1545.
9.
Ioannou Y., Pericleous C., Giles I., Latchman DS, Isenberg DA, Rahman A.Binding of antiphospholipid antibodies to discontinuous epitopes on domain I of human beta2-glycoprotein I: mutation studies including residues R39 to R43. Arthritis Rheum2007; 56: 280-290.
10.
Ioannou Y., Romay-Penabad Z., Pericleous C., et al. In vivo inhibition of antiphospholipid antibody-induced pathogenicity utilizing the antigenic target peptide domain I of beta2-glycoprotein I: proof of concept. J Thromb Haemost2009; 7: 833-842.
11.
Lozier J., Takahashi N., Putnam FWComplete amino acid sequence of human plasma beta 2-glycoprotein I . Proc Natl Acad Sci USA1984; 81: 3640-3644.
12.
Bouma B., de Groot PG, van der Elsen JMH, et al. Adhesion mechanism of human β2-glycoprotein I to phospholipids based on its crystal structure. EMBO J1999 ; 18: 5166-5174.
13.
Ağar C. , de Groot PG, Levels JH, Marquart JA, Meijers JCBeta-glycoprotein I is incorrectly named apolipoproteinH. J Thromb Haemost2009; 7: 235-236.
14.
de Laat B., Derksen Rhwm, van Lummel M., Pennings MT, de Groot PGPathogenic anti-β2-glycoprotein I antibodies recognize domain I of β2-glycoprotein I only after a conformational change. Blood2006; 107: 1916-1924.
15.
Biasiolo A. , Rampazzo P., Brocco T., et al. Anti-beta2 glycoprotein I-beta2 glycoprotein immune complexes in patients with antiphospholipid syndrome and other autoimmune diseases. Lupus1999; 8: 121-126.
16.
Hoeg JM, Segal P., Gregg RE, et al. Characterization of plasma lipids and lipoproteins in patients with beta 2-glycoprotein I (apolipoprotein H) deficiency. The fasting plasma lipids, lipoproteins, and apolipoproteins were evaluated in 5 subjects. Atherosclerosis1985; 55: 25-34.
17.
Sheng Y., Reddel SW, Herzog H., et al. Impaired thrombin generation in beta 2-glycoprotein I null mice . J Biol Chem2001; 276: 13817-13821.
18.
Del Papa N. , Guidali L., Sala A., et al. Endothelial cells as target for antiphospholipid antibodies. Human polyclonal and monoclonal anti-beta 2-glycoprotein I antibodies react in vitro with endothelial cells through adherent beta 2-glycoprotein I and induce endothelial activation. Arthritis Rheum1997; 40: 551-561.
19.
de Groot PG , Horbach DA, Derksen RHProtein C and other cofactors involved in the binding of antiphospholipid antibodies: relation to the pathogenesis of thrombosis. Lupus1996 ; 5: 488-493.
20.
Wahl D., Membre A., Perret-Guillaume C., Regnault V., Lecompte T.Mechanisms of antiphospholipid-induced thrombosis: effects on the protein C system. Curr Rheumatol Rep2009; 11: 77-81.
21.
Lutters BCH , Derksen Rhwm, Tekelenburg WL, Lenting PJ, Arnout J., de Groot PGDimers of β2-glycoprotein I increase platelet deposition to collagen via interaction with phospholipids and the apolipoprotein E receptor 2’. J Biol Chem2003; 278: 33831-33838.
22.
Meroni PL, Gerosa M., Raschi E., Scurati S., Grossi C., Borghi MOUpdating on the pathogenic mechanisms 5 of the antiphospholipid antibodies-associated pregnancy loss. Clin Rev Allergy Immunol2008 ; 34: 332-337.
Satta N., Dunoyer-Geindre S., Reber G., et al. The role of TLR2 in the inflammatory activation of mouse fibroblasts by human antiphospholipid antibodies. Blood2007; 109: 1507-1514.
25.
Pierangeli SS, Vega-Ostertag ME, Raschi E., et al. Toll-like receptor and antiphospholipid mediated thrombosis: in vivo studies. Ann Rheum Dis2007; 66: 1327-1333.
26.
Romay-Penabad Z., Montiel-Manzano MG, Shilagard T., et al. Annexin A2 is involved in antiphospholipid antibody-mediated pathogenic effects in vitro and in vivo. Blood2009; 114: 3074-3083.
27.
Urbanus RT, Pennings MT, Derksen RH, de Groot PGPlatelet activation by dimeric beta2-glycoprotein I requires signalling via both glycoprotein Ib alpha and apolipoprotein E receptor 2’. J Thromb Haemost2008; 6: 1405-1412.
28.
Pennings MTT , van Lummel M., Derksen Rhwm, et al. Interaction of β2-glycoprotein I with members of the low density lipoprotein receptor family. J Thromb Haemost2006; 4: 1680-1690.
29.
May P., Woldt E., Matz RL, Boucher P.The LDL receptor-related protein (LRP) family: an old family of proteins with new physiological functions. Ann Med2007; 39: 219-228.
30.
Mayer H., Duit S., Hauser C., Schneider WJ, Nimpf J.Reconstitution of the Reelin signaling pathway in fibroblasts demonstrates that Dab1 phosphorylation is independent of receptor localization in lipid rafts. Mol Cell Biol2006; 26: 19-27.
31.
Riddell DR, Vinogradov DV, Stannard AK, Chadwick N., Owen JSIdentification and characterization of LRP8 (apoER2’) in human blood platelets. J Lipid Res1999; 40: 1925-1930.
32.
Korschineck I., Ziegler S., Breuss J., et al. Identification of a novel exon in apolipoprotein E receptor 2 leading to alternatively spliced mRNAs found in cells of the vascular wall but not in neuronal tissue. J Biol Chem2001; 276: 13192-13197.
33.
Yang XV, Banerjee Y., Fernández JA, et al. Activated protein C ligation of ApoER2 (LRP8) causes Dab1-dependent signalling in U937 cells. Proc Natl Acad Sci USA2009; 106: 274-279.
34.
Pennings MT , Derksen Rhwm, Urbanus RT, Tekelenburg WL, Hemrika W., de Groot PGPlatelets express three different splice variants of ApoER2 that are all involved in signalling . J Thromb Haemost2007; 5: 1538-1544.
35.
Shen GQ, Li L., Girelli D., et al. An LRP8 variant is associated with familial and premature coronary artery disease and myocardial infarction. Am J Hum Genet2007; 81: 780-791.
36.
Wang L., Wang X., Laird N., Zuckerman B., Stubblefield P., Xu X.Polymorphism in maternal LRP8 gene is associated with fetal growth . Am J Hum Genet2006; 78: 770-777.
37.
Urbanus R., Derksen Rhwm, de Groot PGPlatelets and the antiphospholipid syndrome. Lupus2008; 17: 888-894.
38.
Somanath PR , Malinin NL, Byzova TVCooperation between integrin αvβ3 and VEGFR2 in angiogenesis. Angiogenesis2009 ; 12: 177-185.
39.
Pennings MT , Derksen RH, van Lummel M., et al. Platelet adhesion to dimeric beta2-glycoprotein-I under conditions of flow is mediated by at least two receptors: glycoprotein Ibalpha and APOER2’. J Thromb Haemost2007; 5: 369-377.
40.
White TC, Berny MA, Tucker EI, et al. Protein C supports platelet binding and activation under flow: role of glycoprotein Ib and apolipoprotein E receptor 2. J Thromb Haemost2008; 6: 995-1002.
41.
White-Adams TC, Berny MA, Tucker EI, et al. Identification of coagulation factor XI as a ligand for platelet apolipoprotein E receptor 2 (ApoER2). Art Thromb Vasc Biol2009; 29: 1602-1607.
42.
Liestøl S., Sandset PM, Mowinckel MC, Wisløff F.Activated protein C resistance determined with a thrombin generation-based test is associated with thrombotic events in patients with lupus anticoagulants. J Thromb Haemost2007; 5: 2204-2210.
43.
Weiler H., Ruf W.Activated protein C in sepsis: the promise of nonanticoagulant activated protein C. Curr Opin Hematol2008; 15: 487-493.
44.
Kim HM, Park BS, Kim JI, et al. Crystal structure of the TLR4- MD-2 complex with bound endotoxin antagonist eritoran. Cell2007; 130: 906-917.
45.
Meijers JC, Tekelenburg WL, Bouma BN, Bertina RM, Rosendaal FRHigh levels of coagulation factor XI as a risk factor for venous thrombosis . N Engl J Med2000; 342: 696-701.
46.
Sugi T., McIntyre JACertain autoantibodies to phosphatidylethanolamine (aPE) recognize factor XI and prekallikrein independently or in addition to the kininogens . J Autoimmun2001; 17: 207-214.
47.
Shi T., Iverson GM, Qi JC, et al. Beta 2-glycoprotein I binds factor XI and inhibits its activation by thrombin and factor XIIa: loss of inhibition by clipped beta 2-glycoprotein I. Proc Natl Acad Sci USA2004; 101: 3939-3944.
48.
Urbanus RT, de Groot PG, Derksen RHReply on prolonged bleeding time and lupus anticoagulant: a second paradox in the antiphospholipid syndrome. Arthritis Rheum2005; 52: 1949-1950.
49.
Salmon J., de Groot PGPathogenic role of antiphospholipid antibodies. Lupus2008; 17: 405-411.
